Literature DB >> 11518873

Antimicrobial susceptibilities of Neisseria gonorrhoeae in Kigali, Rwanda, and trends of resistance between 1986 and 2000.

E Van Dyck1, E Karita, S Abdellati, V H Dirk, M Ngabonziza, Y Lafort, M Laga.   

Abstract

BACKGROUND: Plasmid-mediated and chromosomal-mediated resistance of Neisseria gonorrhoeae to penicillin, tetracycline, thiamphenicol, and trimethoprim-sulfamethoxazole has spread dramatically in Africa. Monitoring of antimicrobial susceptibility is a key element in the control of sexually transmitted diseases. GOAL: To document antimicrobial susceptibilities of gonococci isolated during the past 15 years in Kigali, Rwanda. STUDY
DESIGN: Minimal inhibitory concentrations of recently collected gonococcal isolates of eight antimicrobials were determined. The results were compared with data collected for isolates obtained since 1986.
RESULTS: In 1986, 35% of the gonococcal isolates were penicillinase-producing N gonorrhoeae. Tetracycline-resistant N gonorrhoeae appeared in 1989. The prevalence of penicillinase-producing N gonorrhoeae and tetracycline-resistant N gonorrhoeae increased significantly to 70.5% and 89.2%, respectively. Chromosomal resistance to penicillin, tetracycline, and thiamphenicol increased temporarily, then decreased significantly. Chromosomal resistance to trimethoprim-sulfamethoxazole appeared in 1988 and increased to 21.6%. All the isolates were susceptible to ceftriaxone, ciprofloxacin, spectinomycin, and kanamycin.
CONCLUSIONS: This study illustrated the rapidly increasing frequencies of penicillinase-producing N gonorrhoeae and tetracycline-resistant N gonorrhoeae. Chromosomal resistance to thiamphenicol and trimethoprim-sulfamethoxazole excludes these drugs as alternative treatment. Programs for antimicrobial susceptibility surveillance of N gonorrhoeae should urgently be established in Africa.

Entities:  

Mesh:

Year:  2001        PMID: 11518873     DOI: 10.1097/00007435-200109000-00012

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  6 in total

1.  Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda.

Authors:  Makeda Carroll; Ashok Rangaiahagari; Emmanuel Musabeyezu; Donald Singer; Onyema Ogbuagu
Journal:  Am J Trop Med Hyg       Date:  2016-10-31       Impact factor: 2.345

2.  Antimicrobial Susceptibility Testing Patterns of Neisseria gonorrhoeae from Patients Attending Sexually Transmitted Infections Clinics in Six Regions in Tanzania.

Authors:  Said Aboud; Simon N Buhalata; Onduru G Onduru; Mercy G Chiduo; Gideon P Kwesigabo; Stephen E Mshana; Alphaxard M Manjurano; Mansuet M Temu; Coleman Kishamawe; John M Changalucha
Journal:  Trop Med Infect Dis       Date:  2022-06-02

Review 3.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

4.  Antibiotic-resistant Neisseria gonorrhoeae and changes to the 2019 Rwandan National STI Guidelines.

Authors:  Kristin M Wall; Julien Nyombayire; Rachel Parker; Rosine Ingabire; Jean Bizimana; Jeannine Mukamuyango; Amelia Mazzei; Matt A Price; Marie Aimee Unyuzimana; Amanda Tichacek; Susan Allen; Etienne Karita
Journal:  Int J STD AIDS       Date:  2021-12-08       Impact factor: 1.359

5.  Developing and validating a risk algorithm to diagnose Neisseria gonorrhoeae and Chlamydia trachomatis in symptomatic Rwandan women.

Authors:  Kristin M Wall; Julien Nyombayire; Rachel Parker; Rosine Ingabire; Jean Bizimana; Jeannine Mukamuyango; Amelia Mazzei; Matt A Price; Marie Aimee Unyuzimana; Amanda Tichacek; Susan Allen; Etienne Karita
Journal:  BMC Infect Dis       Date:  2021-04-28       Impact factor: 3.090

6.  A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa.

Authors:  Collins Iwuji; Diantha Pillay; Patience Shamu; Mercy Murire; Susan Nzenze; Laura Ashleigh Cox; Saiqa Mullick
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.